ERYTECH Pharma's Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency.

MLA

“ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency.” Biomedical Market Newsletter, vol. 21, June 2012, pp. 1–3. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=77449425&authtype=sso&custid=ns315887.

APA

ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency. (2012). Biomedical Market Newsletter, 21, 1–3.

Chicago

“ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency.” 2012. Biomedical Market Newsletter 21 (June): 1–3. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=77449425&authtype=sso&custid=ns315887.